-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The RACECAT trial is a multi-center, prospective, randomized controlled trial designed to determine suspected acute large vessel occlusion (LVO) with a rapid assessment of arterial occlusion scale (RACE) ≥5 for emergency medical services (EMS) evaluation.
For patients, whether directly transferred to the endovascular treatment center (EVT-SC group) has a higher proportion of good outcomes than transfer to the local stroke center (SC group).
The results of the study will be announced at the International Stroke Conference 2021 (ISC2021).
Author: Medical team doctors report NMT NMT ISC finishing compiler, please do not reprint without authorization.
Study Introduction The trial was completed in June 2020 and included a total of 1401 patient samples.
The main research methods are shown in the figure below.
Main findings: The main analysis found that there was no clinical difference in the 90-day outcome between patients selected by EMS and patients who were finally diagnosed with ischemic stroke (adjusted OR: 0.
990; 95% CI: 0.
789-1.
243).
Among them, 67% of patients with ischemic stroke were diagnosed with LVO, and the proportion of patients who eventually received EVT was 41% in the SC group and 50% in the EVT-SC group.
Conclusion The results of this study suggest that whether patients can benefit from a certain type of transport may depend on the distance from the location of the disease to the EVT center.
Yimaitong compiled from: Secondary Analysis of the Racecat Trial: Benefit of Direct Transfer to an Endovascular Stroke Center According to the Presence of Large Vessel Occlusion and the Transfer Time to the Endovascular Center.
ISC2021.
-neurology), check the latest information of ISC 2021 at the same time! Long press the QR code to follow the ISC 2021 special report ☟☟☟ You can also click "read the original text" to see more ISC 2021 special related content!
For patients, whether directly transferred to the endovascular treatment center (EVT-SC group) has a higher proportion of good outcomes than transfer to the local stroke center (SC group).
The results of the study will be announced at the International Stroke Conference 2021 (ISC2021).
Author: Medical team doctors report NMT NMT ISC finishing compiler, please do not reprint without authorization.
Study Introduction The trial was completed in June 2020 and included a total of 1401 patient samples.
The main research methods are shown in the figure below.
Main findings: The main analysis found that there was no clinical difference in the 90-day outcome between patients selected by EMS and patients who were finally diagnosed with ischemic stroke (adjusted OR: 0.
990; 95% CI: 0.
789-1.
243).
Among them, 67% of patients with ischemic stroke were diagnosed with LVO, and the proportion of patients who eventually received EVT was 41% in the SC group and 50% in the EVT-SC group.
Conclusion The results of this study suggest that whether patients can benefit from a certain type of transport may depend on the distance from the location of the disease to the EVT center.
Yimaitong compiled from: Secondary Analysis of the Racecat Trial: Benefit of Direct Transfer to an Endovascular Stroke Center According to the Presence of Large Vessel Occlusion and the Transfer Time to the Endovascular Center.
ISC2021.
-neurology), check the latest information of ISC 2021 at the same time! Long press the QR code to follow the ISC 2021 special report ☟☟☟ You can also click "read the original text" to see more ISC 2021 special related content!
